Immune checkpoint inhibitors further aggravate proteinuria in patients with metastatic renal cell carcinoma after long-term targeted therapy

BACKGROUND: Increasing number of patients with metastatic renal cell carcinoma (mRCC) are receiving subsequent programmed cell death protein-1 (PD-1) inhibitor combination therapy following tyrosine-kinase inhibitor (TKI) resistance. To explore whether PD-1 inhibitor would further deteriorate protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Kang, Wu, Zeshen, Zou, Xiangpeng, Liu, Huiming, Wu, Yi, Xiong, Longbin, Yu, Chunping, Guo, Shengjie, Han, Hui, Zhou, Fangjian, Dong, Pei, Zhang, Zhiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984970/
https://www.ncbi.nlm.nih.gov/pubmed/35402197
http://dx.doi.org/10.21037/tau-21-1015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984970/
https://www.ncbi.nlm.nih.gov/pubmed/35402197
http://dx.doi.org/10.21037/tau-21-1015

Ejemplares similares